Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pseudoephedrine Will Be Behind The Counter Across The Country By October

This article was originally published in The Tan Sheet

Executive Summary

Retailers will have to be prepared to enforce monthly gram purchase limits on pseudoephedrine products by mid-April, once meth control provisions of the Patriot Act reauthorization bill go into effect

You may also be interested in...



PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach

Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.

PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach

Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.

Zephrex-D Efficacy Claim Passes NAD Review After Nexafed Firm Objects

NAD says that Westport Pharmaceuticals supported claims for Zephrex-D’s rate of relief and efficacy challenged by Acura Pharmaceuticals, manufacturer of Nexafed, another nonprescription PSE drug formulated to prevent extraction of the ingredient.

Related Content

Topics

UsernamePublicRestriction

Register

PS099159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel